
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded troche containing promethazine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing promethazine are listed in tablet, solution, injection, suppository and syrup forms. No finished promethazine product of any kind is listed in troche form.
Bases for this dose form differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Promethazine is a phenothiazine antihistamine with antiemetic and sedative effects that compounding pharmacies prepare as topical gels, oral liquids and suppositories.
Promethazine is a phenothiazine derivative. It blocks histamine H1 receptors, has weak dopamine-blocking activity (about one tenth that of chlorpromazine) and anticholinergic effects, and the combination produces its antihistamine, antinausea and sedating actions. Manufactured promethazine hydrochloride is sold as tablets, oral syrup, rectal suppositories (for example Padagis) and injection. The labels list FDA-approved uses including seasonal and perennial allergic rhinitis, allergic conjunctivitis, mild urticaria and angioedema, adjunctive treatment of anaphylaxis after acute symptoms are controlled, nausea and vomiting associated with anesthesia and surgery, motion sickness, and preoperative, postoperative and obstetric sedation. Prescribers may order promethazine compounded as a topical gel for a patient who cannot swallow or keep down an oral dose, as an oral liquid in a different vehicle, or in combination with another antiemetic in one preparation. Compounded promethazine preparations are not FDA-approved and require a prescription.
Promethazine labels carry a boxed warning: it should not be used in children under 2 years because of fatal respiratory depression, and the injection label adds severe tissue injury, including gangrene, regardless of parenteral route. Other label warnings include central nervous system depression that impairs driving, potentially fatal respiratory depression in people with COPD or sleep apnea, neuroleptic malignant syndrome, a lowered seizure threshold, bone marrow suppression and cholestatic jaundice. Alcohol, opioids, sedatives, tricyclic antidepressants and other sedating drugs add to its effects; monoamine oxidase inhibitors can increase movement side effects. It should not be used by anyone in a coma, to treat asthma or other lower airway symptoms, or by people who have reacted to a phenothiazine, and MedlinePlus notes it is generally not advised for adults over 65. The label says to use it in pregnancy only if the benefit justifies the risk. Milk levels have not been published; a drugs.com breastfeeding review says occasional short-term use appears low risk, to watch infants for sedation with repeated doses, and that early postpartum use may delay milk coming in. For drowsiness, dry mouth or dizziness, talk to your prescriber or pharmacist; get help right away for slowed breathing, fever with stiffness, or abnormal movements.
Promethazine is an H1 antagonist with antidopaminergic (mesolimbic D2), alpha-adrenergic and antimuscarinic activity. Promethazine is well absorbed from the gastrointestinal tract; after oral dosing, onset is about 20 minutes, duration 4 to 6 hours and up to 12; hepatic metabolism yields sulfoxide and N-desmethyl metabolites excreted in urine; plasma half-life is 9 to 16 hours after IV dosing and about 9.8 hours after IM dosing. A pilot study of a compounded pluronic lecithin organogel reported absolute bioavailability of about 2 percent versus IV in 15 healthy men, with systemic absorption and sedation in at least half of subjects (Glisson et al., IJPC 2005). Labeled indications for promethazine hydrochloride tablets, syrup, suppositories and injection: allergic rhinitis and conjunctivitis, urticaria and angioedema, allergic reactions to blood or plasma, adjunct in anaphylaxis, sedation, nausea and vomiting with anesthesia or surgery, adjunct to postoperative analgesics, and motion sickness. Compounded topical promethazine gel has been studied for systemic absorption (Glisson et al., IJPC 2005); StatPearls lists nausea and vomiting of pregnancy as an off-label use after preferred agents fail. Dosing is per prescriber. Monitoring: injection sites; extrapyramidal and anticholinergic effects; CNS and respiratory depression; false pregnancy test and glucose tolerance results. Epinephrine should not be used for its hypotension. Not a controlled substance.
Wash and dry your hands. Place the troche between your cheek and gum or under your tongue, as your label directs, and let it dissolve. Do not chew or swallow it whole unless told to. Dissolving can take up to 30 minutes. Follow your label about eating or drinking around the dose.
Troches are nonaqueous, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in the closed container in a cool, dry place at room temperature, away from heat so they do not soften, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 troche between cheek and gum and let slowly dissolve